Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • All measurements are in fact targets, whether intended or not; Goodhart's Law does not describe human error but a fundamental problem with measurement itself

    60% confidence
  • Unless something can be measured, it cannot be improved; therefore the goal is to collect personal tools that assist in quantifiable measurement of the self

    60% confidence
  • Whatever amount of personal data you are currently collecting will never feel sufficient; measurement begets more measurement as trackers continuously offer new metrics—heart rate variability, stress, exercise readiness, cardiovascular age

    60% confidence
  • Value capture occurs when you adopt external sources of measurement and let them rule you without adapting them to suit your life, outsourcing your values and your own sense of meaning to an external metric or ranking

    60% confidence
  • When a measure becomes a target, it ceases to be a good measure

    60% confidence
  • Value capture afflicts institutions across every domain: restaurants chase Yelp ratings over food quality; students chase GPA over education; scientists chase grants over truth; pastors compete on baptism rate leaderboards over spiritual development

    60% confidence
  • Metrics inevitably redefine your core sense of what's important, whether you're aware of the trap or not; more personal or nuanced goals are ultimately replaced with simplified metrics or rankings

    60% confidence
  • Metrics inevitably present one direction or option as better—longer lifespans, faster student graduation rates, more page views, higher customer satisfaction scores—making all measurements inherently directional targets

    60% confidence
  • Quantification is a 'technology of distance' that minimizes the need for intimate knowledge and personal trust; metrics travel easily between contexts and are easy to grasp, but achieving that clarity requires simplifying the measured thing and jettisoning nuanced, qualitative information

    60% confidence
  • We have become so accustomed to seeing the world through numbers that it has deprived us of the language to express what is fundamental and valuable about our own humanity, which is urgently needed to answer what humans and AI are each for

    60% confidence
  • After over a decade of tracking heart rate, steps, active calories, sleep, story engagement time, and stress levels, the author gained virtually nothing in terms of self-knowledge; the more he used numerical proxies, the worse he felt about everything

    60% confidence
  • If humans insist on expressing worth through attentional metrics and productivity scores, and turn intelligence and creativity into AI benchmarks, machines will always surpass us because that is literally what they are built to do; the answer is not to turn ourselves into machines

    60% confidence
  • Any institutional quantification requires the evaluation procedure and its product to be comprehensible across contexts, which profoundly limits what the metric can measure; value capture results from internalizing that decontextualized nugget and guiding life by it

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com